CommercialCoverageMedium impact
11.14.07y, Intra-Articular Injection of Hyaluronan for the Treatment of Osteoarthritis
Independence Blue Cross·Orthopedics, Rheumatology, PM&R (Physical Medicine & Rehab) +2 more·Pharmacy
Effective date
Dec 1, 2025
We identified it
Jun 19, 2026
Summary
IBX updated medical necessity criteria for intra-articular hyaluronan injections used to treat osteoarthritis. The policy change affects commercial plans and establishes new requirements for coverage approval of these joint injection treatments.
Action Required
By December 1, 2025: Billing team must review updated medical necessity criteria for hyaluronan joint injections on IBX commercial plans. Update prior authorization workflows and provider documentation requirements for osteoarthritis treatments. Ensure clinical staff document medical necessity according to new IBX criteria to prevent claim denials.